2-Carba cyclic phosphatidic acid regulates blood coagulation and fibrinolysis system for repair after brain injury

Brain Res. 2023 Nov 1:1818:148511. doi: 10.1016/j.brainres.2023.148511. Epub 2023 Jul 26.

Abstract

Effective blood coagulation prevents inflammation and neuronal loss after brain injury. 2-Carba-cyclic phosphatidic acid (2ccPA), a biotherapeutic for brain injury, inhibits blood extravasation resulting from blood-brain barrier breakdown. However, the hemostasis mechanism of 2ccPA remains unclear. We determined the effects of 2ccPA-injection on blood coagulation and fibrinolysis using a needle-induced brain injury model. 2ccPA suppressed the expression of platelet degranulation-related genes. Immediately after brain injury, 2ccPA increased CD41+ platelet aggregation around the lesions and promoted fibrin aggregation. Additionally, 2ccPA supported fibrinolysis by upregulating plasminogen activator expression. These results suggest the acute effects of 2ccPA on brain hemostasis.

Keywords: Blood coagulation; Cyclic phosphatidic acid; Fibrinolysis; Traumatic brain injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Coagulation
  • Brain Injuries* / drug therapy
  • Fibrinolysis* / physiology
  • Humans
  • Phosphatidic Acids / pharmacology

Substances

  • 2-carba-cyclic phosphatidic acid
  • Phosphatidic Acids